MRUS News and Press, Merus N.V. From 05/26/22

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT - Investor call to discus...

The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus N.V. (MRUS) Investor Presentation - Slideshow

Citi, which has a buy rating on Merus (NASDAQ:MRUS), is adding the biotech to its Catalyst Watch list ahead of presenting updated early-stage data on zenocutuzumab at the American Society of Clinical Oncology (OTC:ASCO) meeting in June. The firm lowered its price target by $1 to $37 (~134% up...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...

Merus press release (NASDAQ:MRUS): Q1 GAAP EPS of -$0.43 beats by $0.22. Revenue of $11.66M (+39.6% Y/Y) beats by $2.29M. For further details see: Merus GAAP EPS of -$0.43 beats by $0.22, revenue of $11.66M beats by $2.29M

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. CT - Clinical data update of petosemtamab (Peto) and MCLA-129 planned for...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioNTech ( BNTX ) rose to fame with the tech that delivered the Pfizer ( PFE ) vaccine, but there’s more there than just the vaccine. BioCryst Pharmaceuticals ( BCRX ) is a commercial-stage biote...

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells – MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20...